New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on ...

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-G…

Iopofosine I 131 is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a ...

Biogen Inc.: Health Canada Grants Authorization for "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
Pharmabiz

Health Canada grants authorization for Leqembi to treat early Alzheimer’s disease

Health Canada grants authorization for Leqembi to treat early Alzheimer’s disease: Stockholm Tuesday, October 28, 2025, 10:00 Hrs [IST] BioArctic AB’s (publ) partner Eisai ann ...

Cellectar Biosciences stock soars after FDA grants rare pediatric designation

Investing.com -- Cellectar Biosciences (NASDAQ:CLRB) stock surged 27% after the company received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for its iopofosine I 131 ...
InvestorsHub on MSN

Cellectar Biosciences stock jumps after FDA grants Rare Pediatric Disease Designation

Cellectar Biosciences (NASDAQ:CLRB) shares soared 27% after the company received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for its iopofosine I 131 therapy ...